NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

LYNPARZA Pancreas Cancer Japan Post-Marketing Surveillance (PMS)

CompletedN/A

Sponsor: AstraZeneca

Conditions: Pancreatic Neoplasms

Countries: Japan

To collect and characterise the incidence of adverse events related to the safety specifications of the maintenance treatment after platinum-based chemotherapy in patients with BRCA mutated pancreatic cancer under the actual post-marketing use of LYNPAZA.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patients who receive LYNPARZA for the first time for the maintenance treatment after platinum-based chemotherapy in patients with BRCA mutated curatively unresectable pancreas cancer after the approval date of partial change application for the additional indication (25/Dec./2020).

Exclusion Criteria:

* Patients who have no treatment history with LYNPARZA

Locations (60)

Osaka, Lyn010001, Japan
Kanagawa, Lyn010003, Japan
Okayama, Lyn010004, Japan
Akita, Lyn010005, Japan
Niigata, Lyn010006, Japan
Shizuoka, Lyn010007, Japan
Niigata, Lyn010008, Japan
Tokyo, Lyn010009, Japan
Saitama, Lyn010010, Japan
Aichi, Lyn010011, Japan
Osaka, Lyn010012, Japan
Tokyo, Lyn010013, Japan
Nara, Lyn010014, Japan
Wakayama, Lyn010015, Japan
Miyagi, Lyn010016, Japan
Tokyo, Lyn010017, Japan
Osaka, Lyn010018, Japan
Gunma, Lyn010019, Japan
Hiroshima, Lyn010020, Japan
Tochigi, Lyn010021, Japan
Numakunai, Lyn010022, Japan
Osaka, Lyn010025, Japan
Shizuoka, Lyn010026, Japan
Nagasaki, Lyn010027, Japan
Kumamoto, Lyn010028, Japan
Saitama, Lyn010029, Japan
Nagano, Lyn010031, Japan
Hyōgo, Lyn010032, Japan
Shimane, Lyn010033, Japan
Hyōgo, Lyn010034, Japan
+ 30 more on CT.gov